Abstract Library

#804 The Plasma Chromogranin A Level Predicts Survival and Tumor Response in Patients with Gastroenteropancreatic Neuroendocrine Tumors

Introduction: The plasma chromogranin A (CgA) level is a reliable biomarker for identifying patients with advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs).

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author: Chou W

Authors: Chou W, Chen J, Hsu J, Chen T, Hung Y,

Keywords: neuroendocrine tumor, biomarker, chromogranin A,

#458 Octreotide Long-Acting ReleaseTherapy for Patients with Functional and Metastatic Gastroenteropancreatic Neuroendocrine Tumors: A Retrospective Analysis in Chang-Gung Memorial Hospital

Introduction: Reports of octreotide therapy for symptomatic control in patients with functioning gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in Asia are lacking.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Chia-Hsun H, Wen-Chi C, Yung-Chang L, Chaung-Chi L, Rong-Nan C,

Keywords: functioning gastroenteropancreatic neuroendocrine tumors, Octreotide LAR ,

#428 Clinical Manifestations of Patients with Pancreatic ß Cells Hyperplasia

Introduction: Pathologic hyperplasia of pancreatic endocrine cells is uncommon. ß cell hyperplasia contributes to persistent hyperinsulinemic hypoglycemia. The manifestations of patients with pancreatic ß cells hyperplasia are variable and their preop. diagnosis is difficult.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Hwang T, Hsu J, Shan Y,

Keywords: ß cell hyperplasia,